News and Press Releases
Myonex Announces Acquisition of Safeway Compounding Pharmacy to Expand its Clinical Trial Services Across the US
9 April 2024 -- Horsham, US -- Myonex, a leading global clinical trial supply company, has completed the acquisition of SaveWay Compounding Pharmacy of Newark, US. The pharmacy will operate as...
Category: Clinical Trials
Posted: April 9, 2024
Nonacus launches test for comprehensive genomic profiling, integrated with bioinformatics and analysis software
2 April 2024 -- Birmingham, UK -- Genetic testing company, Nonacus, has launched GALEAS Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumours, allowing clinicians...
Category: Biotechnology
Posted: April 2, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham B32 1AF, United Kingdom
Bora Pharmaceuticals completes the acquisition of Upsher-Smith
Acquisition expands Bora’s North American footprint with first US manufacturing site 1 April 2024 -- Taipei, Taiwan -- Bora Pharmaceuticals today announced that it has completed the acquisition of Upsher-Smith Laboratories,...
Category: BioManufacturing
Posted: April 1, 2024
6F., No. 2, Aly. 36, Ln. 26, Ruiguang Rd., Neihu District, Taipei City, 114 Taiwan
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
27 March 2024 -- Princeton, US, and Frankfurt, Germany -- Indegene, a digital-first, life sciences commercialisation company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider...
Category: Pharmaceutical
Posted: March 27, 2024
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthenpipeline in cardiovascular disease
25 March, 2024 -- Bagsværd, Denmark, and Hannover, Germany -- Novo Nordisk and CardiorPharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to€1.025bn, including an upfront...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 26, 2024
Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...
Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team
6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...
Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer
First time GMP manufacturing of a therapeutic IgE antibody has been achieved at scale GMP material to be used in phase 1b study in platinum-resistant ovarian cancer (PROC) patients scheduled...
Category: BioManufacturing
Posted: March 5, 2024
FGK Clinical Research GmbH Acquires Clinicology Ltd, Expanding Territorial Footprint in Europe
22 February 2024 -- Munich, Germany -- FGK Clinical Research GmbH, a European-based full-service provider of clinical research services, is thrilled to announce the successful acquisition of Clinicology Ltd, a...
Category: Clinical Trials
Posted: February 22, 2024
Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early
7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...
Category: Biotechnology
Posted: February 7, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF
First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...
Category: Drug Discovery
Posted: February 7, 2024
Greenphire Announces Acquisition of Clincierge to Enhance Clinical Trial Support Services
Addition enables sponsors to solve the number one clinical trial participant obstacle – transportation, with a single industry-leading solution 1 February 2024 -- Pennsylvania, US -- Greenphire, a leading innovator in...
Category: Clinical Trials
Posted: February 1, 2024
Calypso Enters into Agreement to Be Acquired by Novartis
Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications The acquisition of Calypso gives Novartis...
Category: Biotechnology
Posted: January 8, 2024
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT▼(amivantamab) Plus Lazertinib Resulted in 30% Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC
Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from...
Category: Clinical Trials
Posted: October 24, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...
Category: Clinical Trials
Posted: October 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
